Stout’s Healthcare Financial Due Diligence team delivered a detailed quality-of-earnings analysis focused on key financial considerations, such as revenue recognition timing differences, accrued compensation, normalization of non-recurring sales commissions, and other adjustments to operating expenses, to a leading purpose-built pharmaceutical services platform.

The engagement included extensive net working capital diligence, identifying deferred revenue as a critical component affecting deal economics. We worked closely with the client from kickoff through closing, providing strategic counsel on purchase agreement provisions, transaction rollforward procedures, and working capital mechanics. This proactive partnership ensured the buyer had complete visibility into transaction risks and opportunities.

In addition, our Valuation Advisory and Accounting & Reporting Advisory teams completed the opening balance sheet, which encompassed the fair value assessment of acquired intangible assets.